ESTRO 2024 - Abstract Book

S2351

Clinical - Urology

ESTRO 2024

Material/Methods:

A total of 62 patients with refractory HCC to TACE or RFA received SABR from 2015 to 2021, with a follow- up of ≥12 months. All patients had preserved liver function and no evidence of extrahepatic lesions.

Results:

With median follow-up duration of 36.5 months, the local control rate (LC), progression-free survival (PFS), and overall survival (OS) at 2 years were 78.1%, 37.0%, and 82.1%, respectively. In multivariate analysis, decreasing levels of AFP ( p =0.032) and PIVKA-II through SABR ( p =0.025) were associated with a good prognosis for LC. An AFP level of ≤4.5 IU/mL ( p =0.017) and PIVKA- II level of ≤22 mAU/mL after SABR ( p =0.005) were found to be significant prognostic factors for PFS. For OS, a PIVKA- II level of ≤22 mAU/mL after SABR ( p =0.025) and a decreasing level of PIVKA-II through SABR ( p =0.005) were independent factors.

Conclusion:

SABR could be an alterative treatment option for patients with hepatocellular carcinoma who do not respond to TACE or RFA. Tumor markers such as AFP and PIVKA-II could be useful clinical tools to predict treatment outcomes in patients with HCC refractory to TACE or RFA who are receiving SABR.

Keywords: SABR, HCC, PIVKA-II

771

Digital Poster

Hypofractionated dose-escalated salvage RT for macroscopic prostate cancer local recurrence

Alessandra Castelluccia, Francesco Tramacere, Marzia Borgia, Maurizio Portaluri

"A. Perrino" Hospital, Radiotherapy, Brindisi, Italy

Purpose/Objective:

Emerging data indicate comparable outcomes of standard postoperative fractionation and moderate hypofractionation radiation therapy (RT) in prostate cancer, but the optimal schedule of post-prostatectomy radiotherapy remains to be established. An escalation of the radiotherapy (RT) dose is often considered for controlling the visible tumor mass, in case of detection macroscopic local recurrence. The purpose of this study was to assess the tolerability of dose-escalated hypofractionated salvage radiotherapy (HSRT) for local macroscopic prostate cancer recurrence.